Fem 7 Combi

Pharmaceutical System transdermalny

faza I: 50 mcg/24 h (1,5 mg); faza II: 50 mcg/24 h (1,5 mg) + 10 mcg/24 h (1,5 mg) Dosage

faza I: 50 mcg/24 h (1,5 mg); faza II: 50 mcg/24 h (1,5 mg) + 10 mcg/24 h (1,5 mg) Strength

- Pack Size

System transdermalny Form

Pharmaceutical

Advanced pharmaceutical formulation for targeted therapeutic intervention.

faza I: 50 mcg/24 h (1,5 mg); faza II: 50 mcg/24 h (1,5 mg) + 10 mcg/24 h (1,5 mg)

faza I: 50 mcg/24 h (1,5 mg); faza II: 50 mcg/24 h (1,5 mg) + 10 mcg/24 h (1,5 mg)

System transdermalny

Rejestry E-zdrowia

View Source

" data-Components--Molecules--Slider--slider-target="navigationNext" >

Generic Class

Scan this QR code to access this page quickly on your mobile device.

Language